Bellerophon Therapeutics Inc (PK:BLPH)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 184 Liberty Corner Road, Suite 302
WARREN NJ 07059
Tel: N/A
Website: www.bellerophon.com
IR: See website
<
Key People
Craig R. Jalbert
President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Treasurer, Company Secretary, Director
Bobae Kim
Vice President - Regulatory Affairs and Quality Assurance
 
Business Overview
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company's focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company's INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company's subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
Financial Overview
For the nine months ended 30 September 2023, Bellerophon Therapeutics Inc revenues increased from $0K to $5.6M. Net loss decreased 71% to $4.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 53% to $5.8M (expense), Interest income increase from $67K to $296K (income).
Employees: 18 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $5.64M as of Sep 30, 2023
EBITDA (TTM): -$11.03M as of Sep 30, 2023
Net annual income (TTM): -$9.25M as of Sep 30, 2023
Free cash flow (TTM): -$12.34M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 12,232,648 as of Nov 10, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.